JUN Specifies the Local Differentiation and Maintenance of Pro-tumoral Monocyte-Derived Macrophages

Marcello Delfini1, Elodie Baudoin1, Guo Guo1,2

  • 1Centre d'Immunologie de Marseille-Luminy (CIML), CNRS, INSERM, Aix-Marseille Universite, Marseille, France.

Cancer Research
|May 29, 2026
PubMed

Insights

The AP-1 factor JUN drives pro-tumoral functions in monocyte-derived macrophages (MDMs), a key component of tumor-associated macrophages (TAMs). Targeting JUN may offer selective cancer therapies.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumor-associated macrophages (TAMs) are crucial in cancer progression and therapy resistance.
  • TAMs consist of resident tissue macrophages (RTMs) and monocyte-derived macrophages (MDMs), with distinct roles in tumorigenesis.
  • RTMs are linked to trophic functions, while MDMs are involved in immune regulation.

Purpose of the Study:

  • To investigate the specific role of the AP-1 factor JUN in TAM differentiation and function.
  • To determine JUN's involvement in pro-tumoral versus immune-regulatory pathways within TAMs.
  • To explore JUN's potential as a therapeutic target for cancer treatment.

Main Methods:

  • Utilized single-cell transcriptomics to analyze tumor-infiltrating monocytes and TAM states.
  • Investigated the function of the JUN factor in macrophage differentiation and maintenance.
  • Assessed the impact of JUN on TAM-associated trophic and immune-regulatory functions.

Main Results:

  • JUN is specifically required for the differentiation and maintenance of pro-tumoral MDMs.
  • JUN drives trophic functions in TAMs, supporting blood vessel maturation and tumor growth.
  • Immune-regulatory functions of TAMs were found to be JUN-independent.

Conclusions:

  • JUN plays a critical role in specifying pro-tumoral monocyte-derived TAMs.
  • JUN-dependent TAMs contribute to tumor growth by promoting vascularization.
  • Targeting JUN offers a potential strategy for selective TAM-based cancer therapies.